{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T21:27:51Z","timestamp":1779312471485,"version":"3.51.4"},"reference-count":65,"publisher":"American Veterinary Medical Association (AVMA)","license":[{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ajvr"],"published-print":{"date-parts":[[2023,3,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:p>The goal of pharmacokinetic (PK) studies is to provide a basis for appropriate dosing regimens with novel therapeutic agents. With a knowledge of the desired serum concentration for optimum pharmacological effect, the amount and rate of drug administration can be tailored to maintain that concentration based on the 24-hour PK modeling (eg, every 24 hours, every 12 hours) to achieve therapeutic ranges. This dosing and PK information are tailored to maintain that concentration. Typically, these optimum serum concentrations pertain across species. Single-dose PK modeling provides fundamental parameters to suggest dosing regimes. Multiple-dose PK studies provide information on steady-state serum levels to assure that desired therapeutic levels are maintained during chronic administration. Clinical trials using dosing suggested by these PK determinations provide proof that the compound is producing the desired therapeutic effect. A number of PK studies with cannabinoids in humans and domestic animals have been conducted with the goal of determining appropriate clinical use with these plant-derived products. The following review will focus on the PK of cannabidiol (CBD) and the lesser-known precursor of CBD, cannabidiolic acid (CBDA). Although \u03949-tetrahydrocannabinol (THC) has profound pharmacological effects and may be present at variable and potentially violative concentrations in hemp products, PK studies with THC will not be a major consideration. Because, in domestic animals, hemp-CBD products are usually administered orally, that route will be a focus. When available, PK results with CBD administered by other routes will be summarized. In addition, the metabolism of CBD across species appears to be different in carnivorous species compared with omnivorous\/herbivorous species (including humans) based on current information, and the preliminary information related to this will be explained with the therapeutic implication being addressed in Currents in One Health by Ukai et al, <jats:italic>JAVMA<\/jats:italic>, May 2023.<\/jats:p>","DOI":"10.2460\/ajvr.23.02.0031","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T12:30:51Z","timestamp":1679920251000},"page":"1-9","source":"Crossref","is-referenced-by-count":8,"title":["A One Health perspective on comparative cannabidiol and cannabidiolic acid pharmacokinetics and biotransformation in humans and domestic animals"],"prefix":"10.2460","author":[{"given":"Wayne S.","family":"Schwark","sequence":"first","affiliation":[{"name":"Department of Molecular Medicine, Cornell University College of Veterinary Medicine, Ithaca, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph J.","family":"Wakshlag","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Cornell University College of Veterinary Medicine, Ithaca, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1272","reference":[{"key":"B1","series-title":"Front Vet Sci","first-page":"165","article-title":"Pharmacokinetics, safety, and clinical efficacy of cannabidiol treatment in osteoarthritic dogs","volume":"5","author":"Gamble L-J","year":"2018","unstructured":"Gamble L-J, Boesch JM, Frye CW, Schwark WS, Mann S, et al. Pharmacokinetics, safety, and clinical efficacy of cannabidiol treatment in osteoarthritic dogs. Front Vet Sci. 2018;5:165."},{"key":"B2","series-title":"Vet J","first-page":"105913","article-title":"Cannabidiol in canine epilepsy","volume":"6","author":"Potschka H","year":"2022","unstructured":"Potschka H, Bhatti SFM, Tipold A, McGrath S. Cannabidiol in canine epilepsy. Vet J. 2022;6:105913. doi:10.1016\/j.tvjl.2022.105913"},{"key":"B3","series-title":"Drug Metab Disp","first-page":"469","article-title":"Pharmacokinetics of cannabidiol in dogs","volume":"16","author":"Samara E","year":"1988","unstructured":"Samara E, Bialer M, Mechoulam R. Pharmacokinetics of cannabidiol in dogs. Drug Metab Disp. 1988;16:469\u2013473."},{"key":"B4","series-title":"Chem Biodivers","first-page":"1770","article-title":"Human cannabinoid pharmacokinetics","volume":"4","author":"Huestis MA","year":"2007","unstructured":"Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4:1770\u20131777. doi:10.1002\/cbdv.200790152"},{"key":"B5","series-title":"Can J Vet Res","first-page":"178","article-title":"Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs","volume":"82","author":"Bartner LR","year":"2018","unstructured":"Bartner LR, McGrath S, Rao S, Hyatt LK, Wittenburg LA. Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs. Can J Vet Res. 2018;82:178\u2013183."},{"key":"B6","series-title":"Animals","first-page":"832","article-title":"Single-dose pharmacokinetics and preliminary safety assessment with use of CBD-rich hemp nutraceutical in healthy dogs and cats","volume":"9","author":"Deabold KA","year":"2019","unstructured":"Deabold KA, Schwark WS, Wolf L, Wakshlag JJ. Single-dose pharmacokinetics and preliminary safety assessment with use of CBD-rich hemp nutraceutical in healthy dogs and cats. Animals. 2019;9:832. doi:10.3390\/ani9100832"},{"key":"B7","series-title":"Front Vet Sci","first-page":"583404","article-title":"Pharmacokinetic and safety evaluation of various oral doses of a novel 1:20 THC:CBD cannabis herbal extract in dogs","volume":"7","author":"Chicoine A","year":"2020","unstructured":"Chicoine A, Illing K, Vuong S, Pinto KR, Alcorn J, et al. Pharmacokinetic and safety evaluation of various oral doses of a novel 1:20 THC:CBD cannabis herbal extract in dogs. Front Vet Sci. 2020;7:583404."},{"key":"B8","series-title":"Front Vet Sci","first-page":"505","article-title":"Pharmacokinetics of cannabidiol, cannabidiolic acid, \u0394-9 tetrahydrocannabinol, tetrahydrocannabinolic acid and related metabolites in canine serum after dosing with three oral forms of hemp extract","volume":"7","author":"Wakshlag JJ","year":"2020","unstructured":"Wakshlag JJ, Schwark WS, Deabold KA, Talsma BN, Cital S, et al. Pharmacokinetics of cannabidiol, cannabidiolic acid, \u0394-9 tetrahydrocannabinol, tetrahydrocannabinolic acid and related metabolites in canine serum after dosing with three oral forms of hemp extract. Front Vet Sci. 2020;7:505."},{"key":"B9","series-title":"Med Rec Arch","first-page":"2907","article-title":"Twenty-four hour and one-week steady state pharmacokinetics of cannabinoids in two formulations of cannabidiol and cannabidiolic acid rich hemp in dogs","volume":"10","author":"Tittle DJ","year":"2022","unstructured":"Tittle DJ, Wakshlag JJ, Schwark WS, Lyubimov A, Zakharov A, et al. Twenty-four hour and one-week steady state pharmacokinetics of cannabinoids in two formulations of cannabidiol and cannabidiolic acid rich hemp in dogs. Med Rec Arch. 2022;10:2907."},{"key":"B10","series-title":"Vet Anesthes Analg","first-page":"228","article-title":"Nonsteroidal anti-inflammatory drugs in cats: a review","volume":"34","author":"Lascelles BD","year":"2007","unstructured":"Lascelles BD, Court MH, Hardie EM, Robertson SA. Nonsteroidal anti-inflammatory drugs in cats: a review. Vet Anesthes Analg. 2007;34:228\u2013250. doi:10.1111\/j.1467-2995.2006.00322.x"},{"key":"B11","series-title":"J Fel Med Surg","first-page":"1162","article-title":"Safety and tolerability of escalating cannabinoid doses in healthy cats","volume":"23","author":"Kulpa JE","year":"2021","unstructured":"Kulpa JE, Paulionis IJ, Eglit GM, Vaughn DM. Safety and tolerability of escalating cannabinoid doses in healthy cats. J Fel Med Surg. 2021;23:1162\u20131175. doi:10.1177\/1098612X211004215"},{"key":"B12","series-title":"Front Vet Sci","first-page":"895368","article-title":"Serum cannabinoid 24h and 1 week steady state pharmacokinetic assessment in cats using a CBD\/CBDA rich hemp paste","volume":"9","author":"Wang T","year":"2022","unstructured":"Wang T, Zakharov A, Gomez B, Lyubimov A, Trottier NL, et al. Serum cannabinoid 24h and 1 week steady state pharmacokinetic assessment in cats using a CBD\/CBDA rich hemp paste. Front Vet Sci. 2022;9:895368."},{"key":"B13","series-title":"Amer J Vet Res","first-page":"ajvr.22.02.0028","article-title":"Pharmacokinetics of cannabidiol in a randomized crossover trial in senior horses","volume":"83","author":"Turner SE","year":"2022","unstructured":"Turner SE, Knych HJ, Adams AA. Pharmacokinetics of cannabidiol in a randomized crossover trial in senior horses. Amer J Vet Res. 2022;83:ajvr.22.02.0028. doi:10.2460\/ajvr.22.02.0028"},{"key":"B14","series-title":"J Equine Vet Sci","first-page":"103842","article-title":"Pharmacokinetic evaluation of a cannabidiol supplement in horses","volume":"110","author":"Williams MR","year":"2022","unstructured":"Williams MR, Holbrook TC, Maxwell L, Croft CH, Intile MM, et al. Pharmacokinetic evaluation of a cannabidiol supplement in horses. J Equine Vet Sci. 2022;110:103842. doi:10.1016\/j.jevs.2021.103842"},{"key":"B15","series-title":"J Equine Vet Sci","first-page":"103933","article-title":"Pharmacokinetics, safety, and synovial fluid concentrations of single- and multiple-dose oral administration of 1 and 3 mg\/kg cannabidiol in horses","volume":"113","author":"Yocum AF","year":"2022","unstructured":"Yocum AF, O\u2019Fallon ES, Gustafson DL, Contino EK. Pharmacokinetics, safety, and synovial fluid concentrations of single- and multiple-dose oral administration of 1 and 3 mg\/kg cannabidiol in horses. J Equine Vet Sci. 2022;113:103933. doi:10.1016\/j.jevs.2022.103933"},{"key":"B16","series-title":"Drug Test Anal","first-page":"1305","article-title":"Pharmacokinetics and effects on arachidonic metabolism of low doses of cannabidiol following oral administration to horses","volume":"13","author":"Ryan D","year":"2021","unstructured":"Ryan D, McKemie DS, Kass PH, Puschner B. Pharmacokinetics and effects on arachidonic metabolism of low doses of cannabidiol following oral administration to horses. Drug Test Anal. 2021;13:1305\u20131317. doi:10.1002\/dta.3028"},{"key":"B17","series-title":"J Anim Sci","first-page":"3635","article-title":"Factors that affect drug disposition in food-producing animals during maturation","volume":"70","author":"Schwark WS","year":"1992","unstructured":"Schwark WS. Factors that affect drug disposition in food-producing animals during maturation. J Anim Sci. 1992;70:3635\u20133644. doi:10.2527\/1992.70113635x"},{"key":"B18","series-title":"Front Vet Sci","first-page":"789495","article-title":"Plasma pharmacokinetics of cannabidiol following oral administration of cannabidiol oil to dairy calves","volume":"24","author":"Meyer K","year":"2022","unstructured":"Meyer K, Hayman K, Baumgartner J, Gorden PJ. Plasma pharmacokinetics of cannabidiol following oral administration of cannabidiol oil to dairy calves. Front Vet Sci. 2022;24:789495."},{"key":"B19","series-title":"Sci Rep","first-page":"12753","article-title":"Plasma concentrations of eleven cannabinoids in cattle following oral administration of industrial hemp (Cannabis sativa)","volume":"10","author":"Kleinhenz MD","year":"2020","unstructured":"Kleinhenz MD, Magnin G, Lin Z, Griffin J, Kleinhenz KE, et al. Plasma concentrations of eleven cannabinoids in cattle following oral administration of industrial hemp (Cannabis sativa). Sci Rep. 2020;10:12753. doi:10.1038\/s41598-020-69768-4"},{"key":"B20","series-title":"Sci Rep","first-page":"3683","article-title":"Short term feeding of industrial hemp with high cannabidiolic acid (CBDA) content increases lying behavior and reduces biomarkers of stress in inflammation in Holstein steers","volume":"12","author":"Kleinhenz MD","year":"2022","unstructured":"Kleinhenz MD, Weederntgomery M, Martin M, Curtis A, Magnin G, et al. Short term feeding of industrial hemp with high cannabidiolic acid (CBDA) content increases lying behavior and reduces biomarkers of stress in inflammation in Holstein steers. Sci Rep. 2022;12:3683. doi:10.1038\/s41598-022-07795-z"},{"key":"B21","series-title":"Br J Clin Pharmacol","first-page":"2477","article-title":"The pharmacokinetics and pharmacodynamics of cannabinoids","volume":"84","author":"Lucas CJ","year":"2018","unstructured":"Lucas CJ, Galettas P, Schneider J. The pharmacokinetics and pharmacodynamics of cannabinoids. Br J Clin Pharmacol. 2018;84:2477\u20132482. doi:10.1111\/bcp.13710"},{"key":"B22","series-title":"Front Pharmacol","first-page":"1365","article-title":"A systematic review of the pharmacokinetics of cannabidiol in humans","volume":"9","author":"Millar SA","year":"2018","unstructured":"Millar SA, Stone NL, Yates AS, O\u2019Sullivan SE. A systematic review of the pharmacokinetics of cannabidiol in humans. Front Pharmacol. 2018;9:1365."},{"key":"B23","series-title":"Psychopharmacology","first-page":"9","article-title":"Cannabidiol pharmacology and therapeutic targets","volume":"238","author":"Britch SC","year":"2021","unstructured":"Britch SC, Babalonis S, Walsh SL. Cannabidiol pharmacology and therapeutic targets. Psychopharmacology. 2021;238:9\u201328. doi:10.1007\/s00213-020-05712-8"},{"key":"B24","series-title":"The Medicinal Uses of Cannabis and Cannabinoids","first-page":"205","article-title":"Metabolism ad pharmacokinetics of cannabinoids","author":"Hawksworth G","year":"2004","unstructured":"Hawksworth G, McArdle K. Metabolism ad pharmacokinetics of cannabinoids. In: Guy GW, Whittle BA, Robson PJ, eds. The Medicinal Uses of Cannabis and Cannabinoids. Pharmaceutical Press; 2004:205\u2013228."},{"key":"B25","series-title":"Clin Pharmacokinet","first-page":"327","article-title":"Pharmacokinetics and pharmacodynamics of cannabinoids","volume":"42","author":"Grotenhermen F","year":"2003","unstructured":"Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42:327\u2013360."},{"key":"B26","series-title":"J. Cannabis Ther","first-page":"35","article-title":"A single centre, placebo-controlled, four period, crossover, tolerability study assessing, pharmacodynamic effects, pharmacokinetic characteristics and cognitive profiles of a single dose of three formulations of Cannabis Based Medicine Extracts (CBMEs) (GWPD9901), plus a two period tolerability study comparing pharmacodynamic effects and pharmacokinetic characteristics of a single dose of a cannabis based medicine extract given via two administration routes (GWPD9901 EXT)","volume":"3","author":"Guy GW","year":"2004","unstructured":"Guy GW, Flint ME. A single centre, placebo-controlled, four period, crossover, tolerability study assessing, pharmacodynamic effects, pharmacokinetic characteristics and cognitive profiles of a single dose of three formulations of Cannabis Based Medicine Extracts (CBMEs) (GWPD9901), plus a two period tolerability study comparing pharmacodynamic effects and pharmacokinetic characteristics of a single dose of a cannabis based medicine extract given via two administration routes (GWPD9901 EXT). J. Cannabis Ther. 2004:3:35\u201377. doi:10.1300\/J175v03n03_03"},{"key":"B27","series-title":"Clin Pharmacol Drug Dev","first-page":"751","article-title":"Single-dose pharmacokinetics of oral cannabidiol following administration of PTL101: a new formulation based on gelatin matrix pellets technology","volume":"7","author":"Atsmon J","year":"2017","unstructured":"Atsmon J, Heffetz D, Deutsch L, Deutsch F, Sacks H. Single-dose pharmacokinetics of oral cannabidiol following administration of PTL101: a new formulation based on gelatin matrix pellets technology. Clin Pharmacol Drug Dev. 2017;7:751\u2013758. doi:10.10.1002\/cpdd.408"},{"key":"B28","series-title":"Clin Pharmacol Drug","first-page":"285","article-title":"A multiple-dose, randomized, double-blind, placebo-controlled, parallel-group QT\/QTc study to evaluate the electrophysiologic effects of THC\/CBD spray","volume":"2","author":"Sellers EM","year":"2017","unstructured":"Sellers EM, Schoedel K, Bartlett C, Romach M, Russo EB, et al. A multiple-dose, randomized, double-blind, placebo-controlled, parallel-group QT\/QTc study to evaluate the electrophysiologic effects of THC\/CBD spray. Clin Pharmacol Drug. 2017;2:285\u2013294. doi:10.1002\/cpdd.36"},{"key":"B29","series-title":"Ther Drug Monit","first-page":"799","article-title":"Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of D9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract","volume":"27","author":"Nadulski T","year":"2005","unstructured":"Nadulski T, Pragst F, Weinberg G, Roser P, Schnelle M, et al. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of D9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract. Ther Drug Monit. 2005:27:799\u2013810."},{"key":"B30","series-title":"J Addict Med","first-page":"204","article-title":"Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans","volume":"9","author":"Manini AF","year":"2015","unstructured":"Manini AF, Yiannoulos G, Bergamaschi MM, Hernandez S, Olmedo R, et al. Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans. J Addict Med. 2015:9:204\u2013210. doi:10.1097\/ADM.0000000000000118"},{"key":"B31","series-title":"Neuropsychopharmacology","first-page":"1974","article-title":"Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked cannabis","volume":"41","author":"Haney M","year":"2016","unstructured":"Haney M, Malcolm RJ, Babalonis S, Nuzzo PA, Cooper ZD, et al. Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked cannabis. Neuropsychopharmacology. 2016;41:1974\u20131982. doi:10.1038\/npp.2015.367"},{"key":"B32","series-title":"Pharmacotherapy","first-page":"405","article-title":"Food effects on the formulation, dosing, and administration of cannabidiol (CBD) in humans: a systemic review of clinical studies","volume":"41","author":"Silmore LH","year":"2021","unstructured":"Silmore LH, Willmer AR, Capparelli EV, GR Rosania. Food effects on the formulation, dosing, and administration of cannabidiol (CBD) in humans: a systemic review of clinical studies. Pharmacotherapy. 2021:41:405\u2013420. doi:10.1002\/phar.2512"},{"key":"B33","series-title":"J Analyt Toxicol","first-page":"583","article-title":"Pharmacokinetic profile of \u03949-tetrahydrocannabinol, cannabidiol and metabolites in blood following vaporization and oral ingestion of cannabidiol products","volume":"46","author":"Beregia CL","year":"2022","unstructured":"Beregia CL, Spindle TR, Cone EJ, Sholler D, Goffi E, et al. Pharmacokinetic profile of \u03949-tetrahydrocannabinol, cannabidiol and metabolites in blood following vaporization and oral ingestion of cannabidiol products. J Analyt Toxicol. 2022;46: 583\u2013591. doi:10.1093\/jat\/bkab124"},{"key":"B34","series-title":"J Analyt Toxicol","first-page":"109","article-title":"Urinary pharmacokinetic profile of cannabinoids following administration of vaporized and oral cannabidiol and vaporized CBD-dominant cannabis","volume":"44","author":"Spindle TR","year":"2020","unstructured":"Spindle TR, Cone EJ, Kuntz D, Mitchell JM, Bigelow GE, et al. Urinary pharmacokinetic profile of cannabinoids following administration of vaporized and oral cannabidiol and vaporized CBD-dominant cannabis. J Analyt Toxicol. 2020;44:109\u2013125. doi:10.1093\/jat\/bkz080"},{"issue":"5","key":"B35","series-title":"J Vet Pharmacol Ther","first-page":"508","article-title":"Serum cannabidiol, tetrahydrocannabinol (THC), and their native acid derivatives after transdermal application of a low-THC Cannabis sativa extract in beagles","volume":"43","author":"Hannon MB","year":"2020","unstructured":"Hannon MB, Deabold KA, Talsma BN, Lyubimov A, Iqbal A, et al. Serum cannabidiol, tetrahydrocannabinol (THC), and their native acid derivatives after transdermal application of a low-THC Cannabis sativa extract in beagles. J Vet Pharmacol Ther. 2020;43(5):508\u2013511. doi:10.1111\/jvp.12896."},{"key":"B36","series-title":"Biomolecules","first-page":"279","article-title":"Pharmacokinetics of Sativex in dogs: towards a potential cannabidiol-based therapy for canine disorders","volume":"10","author":"Fernandez-Trapero M","year":"2020","unstructured":"Fernandez-Trapero M, Perez-Diaz C, Espejo-Porra F, de Lago E, Fernandez-Ruiz J. Pharmacokinetics of Sativex in dogs: towards a potential cannabidiol-based therapy for canine disorders. Biomolecules. 2020;10:279."},{"issue":"9","key":"B37","series-title":"Animals","first-page":"1505","article-title":"Oral transmucosal cannabidiol oil formulation as part of a multimodal analgesic regimen effects on pain relief and quality of life improvement in dogs affected by spontaneous osteoarthritis","volume":"10","author":"Brioschi FA","year":"2020","unstructured":"Brioschi FA, Di Cesare F, Gioeni D, Rabbogliatti V, Ferrari F, et al. Oral transmucosal cannabidiol oil formulation as part of a multimodal analgesic regimen effects on pain relief and quality of life improvement in dogs affected by spontaneous osteoarthritis. Animals. 2020;10(9):1505. doi:10.3390\/ani10091505"},{"key":"B38","series-title":"Front Vet Sci","first-page":"899940","article-title":"Pharmacokinetics of cannabidiol following intranasal, intrarectal, and oral administration in healthy dogs","volume":"9","author":"Polidoro D","year":"2022","unstructured":"Polidoro D, Temmerman R, Devreese M, Charalambous M, Ham LV, et al. Pharmacokinetics of cannabidiol following intranasal, intrarectal, and oral administration in healthy dogs. Front Vet Sci. 2022;9:899940. doi:10.3389\/fvets.2022.899940"},{"key":"B39","series-title":"Molecules","first-page":"2638","article-title":"S(-)-Cannabidiolic acid, a still overlooked bioactive compound: an introductory review and preliminary research","volume":"25","author":"Formato M","year":"2020","unstructured":"Formato M, Crescente G, Scognamiglio M, Fiorentino A, Pecoraro MT. S(-)-Cannabidiolic acid, a still overlooked bioactive compound: an introductory review and preliminary research. Molecules. 2020;25:2638. doi:10.3390\/molecules25112638"},{"key":"B40","series-title":"Planta Med","first-page":"686","article-title":"Heat exposure of Cannabis sativa extracts affects the pharmacokinetic and metabolic profile in healthy male subjects","volume":"78","author":"Eichler M","year":"2012","unstructured":"Eichler M, Spinedi L, Unfer-Grauwiler S, Bodmer M, Surber C, et al. Heat exposure of Cannabis sativa extracts affects the pharmacokinetic and metabolic profile in healthy male subjects. Planta Med. 2012;78:686\u2013691. doi:10.1055\/s-0031-1298334"},{"key":"B41","series-title":"J Vet Pharmcol Ther","article-title":"Pharmacokinetics and pharmacodynamics of single-dose enteral cannabidiol in horses (Equus caballus)","author":"Thomson ACS","unstructured":"Thomson ACS, McCarrel TM, Lyubimov A, Schwark WS, Mallicote MF, et al. Pharmacokinetics and pharmacodynamics of single-dose enteral cannabidiol in horses (Equus caballus). J Vet Pharmcol Ther. [Submitted for publication]"},{"issue":"10","key":"B42","series-title":"Amer J Vet Res","first-page":"ajvr.2022.01.0006","article-title":"Feeding decreases the oral bioavailability of cannabidiol and cannabidiolic acid in hemp oil in New Zealand White rabbits (Oryctolagus cuniculus)","volume":"83","author":"Rooney TA","year":"2002","unstructured":"Rooney TA, Carpenter JW, KuKanich B, Gardhouse SM, Magnin GC, et al. Feeding decreases the oral bioavailability of cannabidiol and cannabidiolic acid in hemp oil in New Zealand White rabbits (Oryctolagus cuniculus). Amer J Vet Res. 2002;83(10):ajvr.2022.01.0006. doi:10.2460\/ajvr.22.01.0006"},{"key":"B43","series-title":"J Vet Pharmacol Ther","first-page":"245","article-title":"Single dose and chronic oral administration of cannabigerol and cannabigerolic acid-rich hemp extract in fed and fasted dogs: physiological effect and pharmacokinetic evaluation","volume":"45","author":"Amstutz K","year":"2022","unstructured":"Amstutz K, Schwark WS, Zakharov A, Gomez B, Lyubimov A, Ellis K, et al. Single dose and chronic oral administration of cannabigerol and cannabigerolic acid-rich hemp extract in fed and fasted dogs: physiological effect and pharmacokinetic evaluation. J Vet Pharmacol Ther. 2022;45:245\u2013254. doi:10.1111\/jvp.13048"},{"key":"B44","series-title":"Veterinary Pharmacology and Therapeutics","first-page":"8","article-title":"Absorption, distribution, metabolism and elimination","author":"Riviere JE","year":"2018","unstructured":"Riviere JE. Absorption, distribution, metabolism and elimination. In: Reviere J, Papich M, eds. Veterinary Pharmacology and Therapeutics. 10th ed. Wiley Blackwell; 2018:8\u201340."},{"key":"B45","series-title":"Current Drug Metab","first-page":"206","article-title":"Cannabinoids and cytochrome p450 interactions","volume":"17","author":"Zendulka O","year":"2016","unstructured":"Zendulka O, Dovretelova G, Noskova K, Turjap M, Sulcova A, et al. Cannabinoids and cytochrome p450 interactions. Current Drug Metab. 2016;17:206\u2013216. doi:10.2174\/1389200217666151210142051"},{"key":"B46","series-title":"Life Sci","first-page":"165","article-title":"Identification of cytochrome p450 enzymes responsible for metabolism of cannabidiol by human liver microsomes","volume":"89","author":"Jiang R","year":"2011","unstructured":"Jiang R, Yamaori S, Takeda S, Yammamoto I, Watanabe Z. Identification of cytochrome p450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci. 2011;89:165\u2013170. doi:10.1016\/j.lfs.2011.05.018"},{"issue":"1","key":"B47","series-title":"Drug Metab Reviews","first-page":"86","article-title":"Exogenous cannabinioids as substrates, inhibitors and inducers of human drug metabolizing enzymes: a systematic review","volume":"46","author":"Stout SM","year":"2014","unstructured":"Stout SM, Cimino NM. Exogenous cannabinioids as substrates, inhibitors and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Reviews. 2014;46(1):86\u201395. doi:10.3109\/03602532.2013.849268"},{"issue":"4","key":"B48","series-title":"Drug Metab Dispos","first-page":"351","article-title":"Comprehensive predictions of cytochrome p450-mediated in vivo cannabinoid-drug interactions based on reversible and time dependent p450 inhibition in human liver microsomes","volume":"50","author":"Bansal S","year":"2022","unstructured":"Bansal S, Paine MF, Unadkat JD. Comprehensive predictions of cytochrome p450-mediated in vivo cannabinoid-drug interactions based on reversible and time dependent p450 inhibition in human liver microsomes. Drug Metab Dispos. 2022;50(4):351\u2013360. doi:10.1124\/dmd.121.000734"},{"key":"B49","series-title":"CNS Drugs","first-page":"1053","article-title":"A phase 1, randomized, double blinded, placebo controlled, single ascending dose, multiple dose and food effect triol on the safety and tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects","volume":"32","author":"Taylor L","year":"2018","unstructured":"Taylor L, Gidal B, Blakey, G, Tayo B, Morrison G. A phase 1, randomized, double blinded, placebo controlled, single ascending dose, multiple dose and food effect triol on the safety and tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs. 2018;32:1053\u20131067. doi:10.1007\/s40263-018-0578-5"},{"key":"B50","series-title":"Forens Sci Internat","first-page":"114","article-title":"Distribution of free and conjucated cannabinoids in human bile samples","volume":"223","author":"Fabritius M","year":"2012","unstructured":"Fabritius M, Staub C, Mangin P, Giroud C. Distribution of free and conjucated cannabinoids in human bile samples. Forens Sci Internat. 2012; 223:114\u2013118. doi:10.1016\/j.forsciint.2012.08.013"},{"issue":"10","key":"B51","series-title":"Br J Pharmacol","first-page":"1506","article-title":"Species-specific susceptibility to cannabis-induced convulsions","volume":"176","author":"Whalley BJ","year":"2019","unstructured":"Whalley BJ, Lin H, Bell L, Hill T, Patel A, Gray RA, Elizabeth Roberts C, Devinsky O, Bazelot M, Williams CM, Stephens GJ. Species-specific susceptibility to cannabis-induced convulsions. Br J Pharmacol. 2019;176(10):1506\u20131523. doi:10.1111\/bph.14165"},{"key":"B52","series-title":"Pharm Biochem Behav","first-page":"523","article-title":"Comparative metabolism of cannabidiol in dog, rat and human","volume":"40","author":"Harvey DJ","year":"1991","unstructured":"Harvey DJ, Samara E, Mechoulam R. Comparative metabolism of cannabidiol in dog, rat and human. Pharm Biochem Behav. 1991;40:523\u2013532. doi:10.1016\/0091-3057(91)90358-9"},{"key":"B53","series-title":"Pharm Biochem Behav","first-page":"533","article-title":"Comparative in vitro metabolism of the cannabinoids","volume":"40","author":"Harvey DJ","year":"1991","unstructured":"Harvey DJ, Brown NK. Comparative in vitro metabolism of the cannabinoids. Pharm Biochem Behav. 1991;40:533\u2013540. doi:10.1016\/0091-3057(91)90359-A"},{"key":"B54","series-title":"Talanta","first-page":"120537","article-title":"Fast and sensitive UHPLC-MS\/MS analysis of cannabinoids and their acid precursors in pharmaceutical preparations of medical cannabis and their metabolites in conventional and non-conventional biological matrices of treated individual","volume":"209","author":"Pichini S","year":"2020","unstructured":"Pichini S, Mannocchi G, Gottardi M, P\u00e9rez-Acevedo AP, Poyatos L, et al. Fast and sensitive UHPLC-MS\/MS analysis of cannabinoids and their acid precursors in pharmaceutical preparations of medical cannabis and their metabolites in conventional and non-conventional biological matrices of treated individual. Talanta. 2020;209:120537. doi:10.1016\/j.talanta.2019.120537"},{"issue":"6","key":"B55","series-title":"J Vet Pharmacol Ther","first-page":"967","article-title":"Plasma and joint tissue pharmacokinetics of two doses of oral cannabidiol oil in guinea pigs (Cavia porcellus)","volume":"44","author":"Spittler AP","year":"2021","unstructured":"Spittler AP, Helbling JE, McGrath S, Gustafson DL, Santangelo KS, Sadar MJ. Plasma and joint tissue pharmacokinetics of two doses of oral cannabidiol oil in guinea pigs (Cavia porcellus). J Vet Pharmacol Ther. 2021;44(6):967\u2013974. doi:10.1111\/jvp.13026"},{"issue":"12","key":"B56","series-title":"Exp Rev Clin Pharm","first-page":"1443","article-title":"Cannabinoids and drug metabolizing enzymes: potential for drug-drug interactions and implications for drug safely and efficacy","volume":"15","author":"Bardhi K","year":"2022","unstructured":"Bardhi K, Coates S, Watson CJW, Lazarus P. Cannabinoids and drug metabolizing enzymes: potential for drug-drug interactions and implications for drug safely and efficacy. Exp Rev Clin Pharm. 2022;15(12):1443\u20131460. doi:10.1080\/17512433.2022.2148655"},{"issue":"11","key":"B57","series-title":"J Nat Prod","first-page":"3047","article-title":"Pharmacokinetics of phytocannabinoid acids and anticonvulsant effect of cannabidiolic acid in a mouse model of Dravet syndrome","volume":"82","author":"Anderson LL","year":"2019","unstructured":"Anderson LL, Low IK, Banister SD, McGregor IS, Arnold JC. Pharmacokinetics of phytocannabinoid acids and anticonvulsant effect of cannabidiolic acid in a mouse model of Dravet syndrome. J Nat Prod. 2019;82(11):3047\u20133055. doi:10.1021\/acs.jnatprod.9b00600"},{"issue":"10","key":"B58","series-title":"Food Addit Contam Part A Chem Anal Control Expo Risk Assess","first-page":"1705","article-title":"Rapid quantification of cannabinoids in beef tissues and bodily fluids using direct-delivery electrospray ionization mass spectrometry","volume":"39","author":"Chakrabarty S","year":"2022","unstructured":"Chakrabarty S, Serum EM, Winders TM, Neville B, Kleinhenz MD, Magnin G, Coetzee JF, Dahlen CR, Swanson KC, Smith DJ. Rapid quantification of cannabinoids in beef tissues and bodily fluids using direct-delivery electrospray ionization mass spectrometry. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2022;39(10):1705\u20131717. doi:10.1080\/19440049.2022.2107711"},{"key":"B59","series-title":"Cannabis Cannabin Res","first-page":"90","article-title":"Human metabolites of cannabidiol: a review on their formation, biological activity and relevance in therapy","volume":"1.1","author":"Ujvary I","year":"2016","unstructured":"Ujvary I, Hanus L. Human metabolites of cannabidiol: a review on their formation, biological activity and relevance in therapy. Cannabis Cannabin Res. 2016;1.1:90\u2013107. doi:10.1089\/can2015.0012"},{"key":"B60","series-title":"Seizure Eur J Epilep","first-page":"189","article-title":"Interaction of cannabidiol with other antiseizure medications: a narrative review","volume":"86","author":"Gilmartin CGS","year":"2021","unstructured":"Gilmartin CGS, Dowd Z, Parker APJ, Harijan P. Interaction of cannabidiol with other antiseizure medications: a narrative review. Seizure Eur J Epilep. 2021;86:189\u2013196. doi:10.1016\/j.seizure.2020.09.010"},{"issue":"1","key":"B61","series-title":"Am J Vet Res","first-page":"86","article-title":"Drug-drug interaction between cannabidiol and phenobarbital in healthy dogs","volume":"83","author":"Doran CE","year":"2021","unstructured":"Doran CE, McGrath S, Bartner LR, Thomas B, Cribb AE, et al. Drug-drug interaction between cannabidiol and phenobarbital in healthy dogs. Am J Vet Res. 2021;83(1):86\u201394. doi:10.2460\/ajvr.21.08.0120"},{"issue":"11","key":"B62","series-title":"J Am Vet Med Assoc","first-page":"1301","article-title":"Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy","volume":"254","author":"McGrath S","year":"2019","unstructured":"McGrath S, Bartner LR, Rao S, Packer RA, Gustafson DL. Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy. J Am Vet Med Assoc. 2019;254(11):1301\u20131308. doi:10.2460\/javma.254.11.1301"},{"key":"B63","series-title":"Front Vet Sci","first-page":"939966","article-title":"Safety and efficacy of cannabidiol-cannabidiolic acid rich hemp extract in the treatment of refractory epileptic seizures in dogs","volume":"9","author":"Garcia GA","year":"2022","unstructured":"Garcia GA, Kube S, Carrera-Justiz S, Tittle D, Wakshlag JJ. Safety and efficacy of cannabidiol-cannabidiolic acid rich hemp extract in the treatment of refractory epileptic seizures in dogs. Front Vet Sci. 2022;9:939966. doi:10.3389\/fvets.2022.939966"},{"key":"B64","series-title":"J Am Anim Hosp Assoc","first-page":"81","article-title":"Evaluation of the effect of cannabidiol on naturally occurring osteoarthritis-associated pain: a pilot study in dogs","volume":"57","author":"Mejia S","year":"2021","unstructured":"Mejia S, Duerr FM, Griffenhagen G, McGrath S. Evaluation of the effect of cannabidiol on naturally occurring osteoarthritis-associated pain: a pilot study in dogs. J Am Anim Hosp Assoc. 2021;57:81\u201390. doi:10.5326\/JAAHA-MS-7119"},{"key":"B65","series-title":"Vet Dermatol","first-page":"329","article-title":"The effect of a mixed cannabidiol and cannabidiolic acid based oil on client-owned dogs with atopic dermatitis","volume":"33","author":"Loewinger M","year":"2022","unstructured":"Loewinger M, Wakshlag JJ, Bowden D, Peters-Kennedy J, Rosenberg A. The effect of a mixed cannabidiol and cannabidiolic acid based oil on client-owned dogs with atopic dermatitis. Vet Dermatol. 2022;33:329\u2013e77. doi:10.1111\/vde.13077"}],"container-title":["American Journal of Veterinary Research"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/ajvr\/aop\/ajvr.23.02.0031\/ajvr.23.02.0031.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/ajvr\/aop\/ajvr.23.02.0031\/ajvr.23.02.0031.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/ajvr\/aop\/ajvr.23.02.0031\/ajvr.23.02.0031.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T12:30:51Z","timestamp":1679920251000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/ajvr\/aop\/ajvr.23.02.0031\/ajvr.23.02.0031.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,29]]},"references-count":65,"URL":"https:\/\/doi.org\/10.2460\/ajvr.23.02.0031","relation":{},"ISSN":["0002-9645"],"issn-type":[{"value":"0002-9645","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,29]]}}}